Forest Laboratories has bought full rights to a blood-pressure drug co-marketed with Johnson & Johnson.
The bad news just keeps on coming in for manufactures of metal-on-metal hips. This morning, Johnson & Johnson ($JNJ) and Stryker ($SYK) are feeling the heat from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA).
Gorsky hasn't been made available to the media, but colleagues say he's a strong leader and a good communicator.
A new article questions the effectiveness of Dendreon's prostate cancer drug Provenge.
Two Murrieta, CA-based implant makers have been called on the carpet by the FDA for lacking quality control over their manufacturing or assembling processes.
The state claims the company misled doctors about Risperdal and is seeking $1.25 billion in penalties.
As Johnson & Johnson and the state of Arkansas start airing their arguments over Risperdal marketing, the company is going back to court in Texas, where it agreed to pay $158 million to settle a...
The FDA is holding its second day of hearings on whether some prescription medications should become sold OTC.
It takes money to make money and yet another pharmaceutical maker is partnering in a venture capital fund, this one designed to draw drug companies to Quebec.
Drug developers have a new target to pursue in their search for remedies against baldness, which afflicts most males to some degree.